Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

Guna Proboka¹, Andra Tilgase²*, Sergejs Isajevs³,⁴, Agnija Rasa² and Peteris Alberts²

¹ Latvian Oncology Centre, Riga Eastern Clinical University Hospital, Riga, Latvia, ² R&D, International Virotherapy Center, Riga, Latvia, ³ Department of Pathology, Riga Eastern Clinical University Hospital, Riga, Latvia, ⁴ Department of Pathology, Faculty of Medicine, University of Latvia, Riga, Latvia

Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease. Melanoma brain metastases have many severe side effects and, unfortunately, any disease related to the brain has limited therapeutic options due to the blood–brain barrier. The course of the disease after a treatment course is complicated to predict, and it is difficult to obtain long-lasting remission. In this report, we describe a female patient with unknown primary melanoma brain metastasis treated with the oncolytic ECHO-7 virus Rigvir® after brain surgery. The patient has been stable, as monitored by magnetic resonance imaging, for more than 3.8 years with ongoing therapy. The median expected overall survival from the time of diagnosis is approximately 5 months. Additional positive effect could have been gained from use of the intranasal administration route, which is considered effective due to the direct anatomical connection between the nasal cavity and the central nervous system. However, further studies are required to fully understand this mode of drug administration.

**Keywords:** melanoma brain metastasis, melanoma unknown primary, blood–brain barrier, oncolytic virus, ECHO-7 virus, intranasal, Rigvir®

**INTRODUCTION**

A female patient born in 1954 has been reported to have had solar urticaria, chronic cholecystitis, hepatitis A virus infection twice, and frequent tonsillitis. In 2009, the patient had a basal cell carcinoma cutis abdominis removed; however, no surgical specimen or histological/pathological examination is available.

In 2014, the patient complained about severe dizziness after movements and increased fatigue. No headache was observed. The patient has a Ph.D., she is married, has three children, her hobbies include traveling and has an active lifestyle. There is no previous family history of cancer. After contrast-enhanced head and brain magnetic resonance imaging (MRI), the patient was diagnosed with a formation in the craniospinal junction. The patient underwent a planned posterolateral foramen magnum formation extirpation in 23 April 2014 (Figure 1). The surgery lasted for 12 h, and no severe complication was observed. CT scan performed 5 days after surgery showed a minimal residual caudal part of the tumor. The condition of the patient during the postoperative period was satisfactory; progressive renewal of physical endurance with no signs of new essential neurologic deficit was observed.

In order to localize the primary tumor, the patient has undergone several examinations: CT scans of the lungs and abdomen, colonoscopy, endoscopy (not shown), and consultations with a dermatologist and an ophthalmologist. The melanoma primary tumor has not been found.
FIGURE 1 | Contrast-enhanced head and brain magnetic resonance imaging (MRI) scan shows a formation in the craniospinal junction before surgery on 17 March 2014 (A). Contrast-enhanced MRI scan 3 months after surgery shows a minimal, residual caudal part of the tumor on 5 June 2014 (B).

FIGURE 2 | (A) Representative photomicrographs of the melanoma metastasis: epithelioid and spindle cells. Hematoxylin-eosin staining, magnification x40, scale bar is 50 μm. (B) The tumor cells demonstrated marked nuclear pleomorphism with variation in cell size, shape, and staining and increased mitotic activity. Hematoxylin-eosin staining, magnification x200, scale bar is 25 μm. (C) MART-1 immunopositivity in the tumor cells. Immunohistochemical staining method, magnification x200, scale bar is 25 μm. (D) S-100 immunopositivity in the tumor cells. Immunohistochemical staining method, magnification x200, scale bar is 25 μm.

Histological examination showed that the metastasis was composed of spindle and epithelioid cells, with large round and elongated nuclei with prominent vesicular nuclei and large nucleoli and abundant eosinophilic cytoplasm, surrounded by mature collagen bundles. The tumor cells demonstrated marked nuclear pleomorphism with variation in cell size, shape, and staining. Mitotic activity was up to five mitotic figures per high powered field (at magnification x200). Melanin pigment was not observed by hematoxylin eosin staining (Figure 2). Immunohistochemistry demonstrated that the tumor cells were...
weakly positive for HMB-45 and Melan A, strongly positive for MART-1, S-100, and vimentin, and that the Ki-67 index was 35% (Figure 2). BRAF gene mutations in codons V600E, V600K, and V600D were not detected.

The patient declined postoperative radiation therapy, because the metastasis residue was closely located to truncus encephali and; therefore, the risk of complications was estimated as high, and efficacy of the radiotherapy uncertain (at that time, stereotactic radiosurgery was not available in Latvia). Since no BRAF mutation was found, therapy with a BRAF inhibitor was contraindicated; in 2014, CTLA-4 and PD-1 immunotherapy was not registered in Latvia (at the time when the decision on adjuvant therapy was made).

An apparently successful long-term Rigvir treatment of a stage IV M1c melanoma patient has previously been reported. Rigvir monotherapy was prescribed after the patient had developed severe side effects from chemotherapy (1).

Therefore, virotherapy with Rigvir® was chosen. The therapy was started in July 2014 with three intramuscular administrations of 2 ml for three consecutive days with the third divided into 1.5 ml intramuscular and 0.5 ml intranasal administration. Subsequently, administrations were once per week, the first two intramuscular and the third divided into intramuscular and intranasal administration. From January 2015, the administrations were changed to one injection every 2 weeks, and from December 2016, to one every 3 weeks, with every third divided into intramuscular and intranasal administration. The patient has not received any other cancer treatment pre- or postsurgery. Serum clinical chemistry parameters were recorded and graded according to NCI CTCAE. Values above grade 1 were not observed during Rigvir® therapy.

Several follow-up MRI scans of the head and brain have been made (5 June 2014 to 2 August 2016) (Figure 3). All scans show minimal residual tissue of a melanoma metastasis in the anterior spinal cord located in the craniospinal junction without significant changes in structure and size. Signs of central and cortical atrophy (September 2015) and periventricular and subcortical vascular leukoencephalopathy with distinct and converging foci of vascular genesis in cerebral hemispheres were observed. Comparison of the last two scans yields that no change in the focus was observed.

**BACKGROUND**

Melanoma is an aggressive malignancy with an increasing incidence worldwide. It has been noted that malignant melanoma has a high risk for dissemination, both through lymphatic and hematogenous pathways (2).

Usually, the primary tumor of melanoma can be detected on the skin, mucosa, or ocular tissue and is classified as melanoma known primary. However, melanoma may also present without known primary tumor, called melanoma unknown primary. It is estimated that 2–6% of all melanoma patients have unknown primary tumor (3). The pathogenesis of melanoma unknown primary is still not fully understood. Hypothetically, unknown primary melanoma is suggested to arise from primary melanoma that has spontaneously regressed and cannot be detected (4). Other hypotheses suggest that ectopic nevus cells residing in visceral organs, lymph nodes, or the nervous system may also give rise to malignant melanoma. Finally, the patient may have had the formation removed without histological diagnosis or the formation might have been misdiagnosed (3). In cases of recurrence, re-biopsy has been described as a successful approach to suggest the origin of cancer and elucidate possible therapeutic approaches (5).

The brain is a favorable environment for the development of metastases due to processes like migration, proliferation, and angiogenesis (6, 7). Melanoma brain metastases are associated with complications like hemorrhage, increased intracranial pressure, and focal or generalized seizures. In such cases, it is
recognized that it is difficult to attain long-lasting remission after the cancer treatment is stopped. To achieve a favorable disease course, it is necessary to consider multimodality strategies (6–8).

Therapies for melanoma brain metastasis are limited mainly because the blood–brain barrier limits the access of circulating molecules from entering the brain parenchyma; therefore, the use of traditional cytotoxic chemotherapy is limited. The usually prescribed treatments for brain metastases are surgery and/or radiation therapy. For patients with advanced-stage melanoma, BRAF-targeted regimens and immunotherapy have shown some efficacy improving the overall survival. It has been suggested that BRAF-targeted regimens might show efficacy in patients with brain metastases (6, 8).

**DISCUSSION**

The present patient had a basal cell carcinoma excised 5 years prior to the brain metastasis surgery. However, there is no histological record available confirming the basal cell carcinoma diagnosis. In 2014, a melanoma brain metastasis was identified but no primary tumor was found. It is not clear if the basal cell carcinoma might have been misdiagnosed. In contrast, histological examination of the material obtained at the brain surgery has been performed using the appropriate melanoma markers (HMB-45 and Melan A weakly positive, MART-1, S-100, and vimentin strongly positive).

Treatment options for brain metastasis are limited due to the blood–brain barrier. However, picornaviruses, to whom the oncolytic ECHO-7 virus Rigvir® belongs, are known to be able to infect the central nervous system (9, 10). The blood–brain barrier consists of polarized microvascular endothelial cells that restrict access to the central nervous system by forming tight junctions. These junctions confine the flow to macromolecules, ions, and solutes. Several routes have been reported by which viruses can cross the blood–brain barrier: by direct infection of endothelium, by crossing through the paracellular space, and by infecting immune cells that can migrate through the epithelium. Several studies have investigated the possible use of intranasal administration of oncolytic viruses by the stem cells to treat glioblastoma. The intranasal administration route is considered to be one of the most beneficial due to several reasons. First, there is a direct connection between the nasal cavity and the central nervous system, second, it is the only possible mode of administration that is not invasive. Third, it is possible to overcome the blood–brain barrier (11). However, most of these studies were done on rodents, and the difference between human and rodent brain must be taken into consideration. Due to possible benefits of this mode of administration, further research is necessary (12–14).

The median expected overall survival from the time of melanoma brain metastasis diagnosis is approximately 5 months (15). A meta-analysis suggests that the prognosis of melanoma unknown primary is better than that of melanoma known primary (4). The patient described here has been stable for more than 3 years and 9 months, and the virotherapy is still ongoing.

**CONCLUDING REMARKS**

It has been previously suggested that Rigvir® improves the overall survival in patients with stage IB–IIC melanoma (16). The present report describes a melanoma unknown primary brain metastasis patient treated with Rigvir® virotherapy. There are limited options to treat brain metastasis because of the brain–blood barrier. The present patient has been stabilized following Rigvir® virotherapy, suggesting that the oncolytic virus Rigvir® might have reached the brain metastasis. Further studies are necessary to elucidate the possible mechanisms of action.

**AUTHOR CONTRIBUTIONS**

GP is the attending immunologist, oncologist of the patient, and SI carried out the histology and pathology analysis. AT, AR, and PA made substantial contributions to acquisition, analysis, and interpretation of data and drafted the manuscript. All authors have read and approved the final version of the manuscript for publication.

**REFERENCES**

1. Alberts P, Olmne E, Brokāne I, Krašīna Z, Romanovska M, Kupčs K, et al. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-thrice case reports. *APMIS* (2016) 124(10):896–904. doi:10.1111/apm.12576

2. Sandru A, Voinea S, Panaitescu E, Băciu A. Survival rates of patients with metastatic malignant melanoma. *J Med Life* (2014) 7(4):572–6.

3. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. *J Clin Oncol* (2009) 27(21):3489–95. doi:10.1200/jco.2008.18.9845

4. Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. *J Am Acad Dermatol* (2015) 72(1):59–70. doi:10.1016/j.jaad.2014.09.029

5. Roe OD, Wahl SGF. The undifferentiated carcinoma that became a melanoma: a systematic review and meta-analysis of observational studies. *J Med Life* (2015) 27(21):3489–95. doi:10.1200/jco.2008.18.9845

6. Paiva MS, Diego J, Fernandes A, O’Brien J, Alves F, et al. Two heads better than one? Ipilimumab immunotherapy with metastatic malignant melanoma. *J Med Life* (2016) 124(10):896–904. doi:10.1111/apm.12576

7. Kircher DA, Silvis MR, Cho JH, Holmen SL. Melanoma brain metastasis: mechanisms, models, and medicine. *Int J Mol Sci* (2016) 17(9):1468. doi:10.3390/ijms17091468

8. Luke JI, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol* (2017) 14(8):463–82. doi:10.1038/nrclinonc.2017.43

9. Rhoades RE, Tabor-Godwin JM, Tsueng G, Feuer R. Enterovirus infections of the central nervous system review. *Virology* (2011) 411(2):288–305. doi:10.1016/j.virol.2010.12.014

10. Miner JJ, Diamond MS. Mechanisms of restriction of viral neuroinvasion at the blood–brain barrier. *Curr Opin Immunol* (2016) 38:18–23. doi:10.1016/j.coi.2015.10.008

11. Jorgani V, Inturk K, Vyas T, Misea A. Recent patents review on intranasal administration for CNS drug delivery. *Recent Pat Drug Deliv Formul* (2008) 2(1):25–40. doi:10.2174/18722110878331429

12. Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. *Mol Ther* (2014) 22(1):140–8. doi:10.1038/mt.2013.199
13. Dey M, Yu D, Kanojia D, Li G, Sukhanova M, Spencer DA, et al. Intranasal oncolytic virotherapy with CXCR4-enhanced stem cells extends survival in mouse model of glioma. *Stem Cell Reports* (2016) 7(3):471–82. doi:10.1016/j.stemcr.2016.07.024

14. Li G, Bonamici N, Dey M, Lesniak MS, Baivasnikova IV. Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. *Expert Opin Drug Deliv* (2018) 15:1–10. doi:10.1080/17425247.2018.1378642

15. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *Br J Cancer* (2017) 116(12):1558–63. doi:10.1038/bjc.2017.142

16. Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. *Melanoma Res* (2015) 25(5):421–6. doi:10.1097/CMR.0000000000000180

**Conflict of Interest Statement:** GP, PA, AT, and AR are employees of the International Virotherapy Center. SI have no potential conflicts of interest to disclose.

Copyright © 2018 Proboka, Tilgase, Isajevs, Rasa and Alberts. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.